Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01867762 · ClinicalTrials.gov registry record · Phase 2
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 211
- Enrollment target
NCT01867762 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 211 participants.
The verdict
NCT01867762, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 211 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effectiveness and safety of JNJ 49095397 in participants with symptomatic moderate to severe chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG Placebo
- DRUG JNJ 49095397
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2013-09-09 |
| Est. Completion | 2014-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01867762
The ClinicalTrials.gov registry entry for NCT01867762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01867762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01867762 about?
NCT01867762 is a clinical study titled "An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease". The purpose of this study is to assess the effectiveness and safety of JNJ 49095397 in participants with symptomatic moderate to severe chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT01867762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2013-09-09. Estimated completion is 2014-09-01.
What interventions are being tested in trial NCT01867762?
The interventions under investigation include: Placebo (DRUG), JNJ 49095397 (DRUG).
Who is sponsoring clinical trial NCT01867762?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.